# US 11,999,784 B2 · Treatment of peripheral T cell lymphoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,999,784 B2
- Document ID: US11999784B2
- Status: Granted
- Kind: B2
- Application number: 16/451,051
- Filed: 2019-06-25
- Published: 2019-10-17
- Granted: 2024-06-04
- Earliest claimed: 2013-02-14
- Assignees: Innate Pharma
- Applicants: Innate Pharma
- Inventors: Cécile Bonnafous; Hélène Sicard; Renaud Buffet; Mathieu Blery
- Web page: https://patentgrep.com/patent/US11999784B2

## CPC

- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- A61P 35/02: specific for leukemia
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/3061: {Blood cells}
- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- G01N 2333/70503: Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.

## Claims

### Claim 1

A method for detecting NKp46 expression in an individual having refractory celiac disease (RCD) and treating said individual comprising:
a) obtaining a biological sample from the individual, said biological sample comprising RCD cells, contacting said RCD cells with an antibody that binds NKp46 polypeptide, and detecting NKp46 polypeptide expression on the surface of said cells; and
b) treating individuals expressing NKp46 polypeptide on RCD cells with anti-NKp46 antibodies.